Aliases & Classifications for Adenocarcinoma

Aliases & Descriptions for Adenocarcinoma:

Name: Adenocarcinoma 12 52 42 14 69
Adenocarcinomas 12 29 14
Adenocarcinoma, No Subtype 12
Adenocarcinoma Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:299
MeSH 42 D000230
NCIt 47 C2852
UMLS 69 C0001418

Summaries for Adenocarcinoma

Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Adenocarcinoma, also known as adenocarcinomas, is related to fallopian tube adenocarcinoma and anus adenocarcinoma. An important gene associated with Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Abraxane and Cervarix have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and colon, and related phenotypes are Decreased viability and cellular

Wikipedia : 71 Adenocarcinoma (/ˌædᵻnoʊkɑːrsᵻˈnoʊmə/; plural adenocarcinomas or adenocarcinomata... more...

Related Diseases for Adenocarcinoma

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1099)
id Related Disease Score Top Affiliating Genes
1 fallopian tube adenocarcinoma 33.2 CDKN2A ERBB2 PTGS2 TP53
2 anus adenocarcinoma 33.0 EGFR ERBB2 MUC1
3 nasal cavity adenocarcinoma 32.9 ERBB2 MUC1 NTRK3
4 gastroesophageal junction adenocarcinoma 32.9 CCND1 CDH1 EGFR EPCAM KRAS MUC1
5 gallbladder signet ring cell adenocarcinoma 32.8 CDH1 MUC1 TP53
6 bladder colonic type adenocarcinoma 32.7 CCND1 KRAS PTGS2 TGFBR2 TP53
7 in situ pulmonary adenocarcinoma 32.7 CCND1 CDH1 CDKN2A EGFR PTGS2 TP53
8 gastric cancer, somatic 31.6 CDH1 ERBB2 KRAS
9 basophilic carcinoma 31.4 CDH1 EPCAM KRAS MUC1 TP53
10 colorectal cancer 31.1 BIRC5 BRAF CCND1 CDH1 CDKN2A EGFR
11 gastrointestinal stromal tumor 30.2 CDKN2A EGFR KIT NTRK3 TP53 VEGFA
12 linitis plastica 30.1 CDH1 TP53
13 interstitial lung disease 30.0 CDKN2A EGFR TP53 VEGFA
14 sclerosing hemangioma 29.9 CDH1 EGFR ERBB2 MUC1
15 peritoneal mesothelioma 29.9 BRAF CCND1 CDH1 KRAS TP53
16 biliary papillomatosis 29.7 BRAF KRAS MUC1
17 hidradenoma 29.7 BRAF CCND1 CDKN2A EPCAM KRAS TP53
18 ovarian cystadenocarcinoma 29.7 EGFR ERBB2 VEGFA
19 myxedema 29.7 CDKN2A EGFR KRAS TP53
20 clear cell adenofibroma 29.7 CDKN2A TP53
21 marginal zone b-cell lymphoma 29.7 CDKN2A EGFR TP53 VEGFA
22 meige syndrome 29.6 KIT MUC1 TP53
23 basaloid squamous cell carcinoma 29.5 CDH1 EGFR ERBB2
24 papillary adenofibroma 29.5 KRAS MUC1 TP53
25 gestational choriocarcinoma 29.4 KIT TP53 VEGFA
26 adrenal cortical carcinoma 29.4 CDH1 CDKN2A EGFR TP53
27 multinodular goiter 29.3 EGFR ERBB2 KDR KRAS VEGFA
28 oral squamous cell carcinoma 29.3 BRAF CDH1 EGFR KRAS PTGS2 TP53
29 rhinosporidiosis 29.2 CDH1 EGFR EPCAM ERBB2 KRAS MUC1
30 appendix adenocarcinoma 12.1
31 clear cell adenocarcinoma 12.1
32 papillary adenocarcinoma 12.1
33 mucinous adenocarcinoma 12.0
34 pancreatic ductal adenocarcinoma 12.0
35 small intestinal adenocarcinoma 12.0
36 scirrhous adenocarcinoma 11.9
37 aggressive digital papillary adenocarcinoma 11.9
38 tubular adenocarcinoma 11.9
39 hepatoid adenocarcinoma 11.9
40 polymorphous low-grade adenocarcinoma 11.9
41 barrett esophagus/esophageal adenocarcinoma 11.9
42 villous adenocarcinoma 11.9
43 signet ring cell adenocarcinoma 11.9
44 papillary serous adenocarcinoma 11.9
45 endometrial adenocarcinoma 11.9
46 colon adenocarcinoma 11.9
47 gastric adenocarcinoma 11.9
48 cervical adenocarcinoma 11.9
49 breast adenocarcinoma 11.8
50 prostate adenocarcinoma 11.8

Graphical network of the top 20 diseases related to Adenocarcinoma:



Diseases related to Adenocarcinoma

Symptoms & Phenotypes for Adenocarcinoma

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.84 BRAF EGFR KRAS MUC1
2 Decreased viability GR00106-A-0 10.84 KRAS
3 Decreased viability GR00107-A-1 10.84 TGFBR2
4 Decreased viability GR00221-A-1 10.84 ROS1 TGFBR2 CDH1 CDKN2A EGFR KDR
5 Decreased viability GR00221-A-2 10.84 ROS1 KDR NTRK3 KRAS
6 Decreased viability GR00221-A-3 10.84 TGFBR2 CDKN2A ERBB2 KDR
7 Decreased viability GR00221-A-4 10.84 TGFBR2 BRAF CDKN2A EGFR ERBB2 KDR
8 Decreased viability GR00301-A 10.84 BRAF CDH1 KIT KRAS
9 Decreased viability GR00342-S-1 10.84 ROS1
10 Decreased viability GR00381-A-1 10.84 BRAF KRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.17 NAPSA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.17 SMAD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.17 SMAD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.17 EGFR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.17 EGFR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.17 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.17 CCND1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.17 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.17 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.17 CCND1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.17 NAPSA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.17 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.17 CCND1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.17 EGFR NAPSA SMAD4 CCND1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.17 CCND1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.17 EGFR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.17 SMAD4 CCND1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.17 CCND1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.17 SMAD4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.17 SMAD4 EGFR
31 Increased shRNA abundance (Z-score > 2) GR00366-A-45 10.17 NAPSA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.17 SMAD4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.17 NAPSA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.17 SMAD4
35 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.17 SMAD4
36 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.17 SMAD4
37 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.17 SMAD4
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.17 EGFR
39 Decreased substrate adherent cell growth GR00193-A-1 9.92 KIT TGFBR2
40 Decreased substrate adherent cell growth GR00193-A-2 9.92 KIT
41 Decreased substrate adherent cell growth GR00193-A-3 9.92 BRAF
42 Decreased substrate adherent cell growth GR00193-A-4 9.92 BRAF KDR KIT TGFBR2
43 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.85 EGFR EPCAM ERBB2 MUC1 NTRK3 VEGFA
44 Decreased cell migration GR00055-A-1 9.8 BRAF EGFR KDR KRAS MUC1
45 Increased cell viability after pRB stimulation GR00230-A-1 9.46 EGFR ERBB2 KIT TGFBR2
46 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRAF KDR ROS1 SMAD4 TGFBR2

MGI Mouse Phenotypes related to Adenocarcinoma:

44 (show all 27)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 CDH1 CDKN2A EGFR EPCAM ERBB2 KDR
2 cardiovascular system MP:0005385 10.53 BRAF CCND1 CDH1 CDKN2A EGFR EPCAM
3 growth/size/body region MP:0005378 10.49 BRAF CCND1 CDH1 CDKN2A EGFR EPCAM
4 behavior/neurological MP:0005386 10.48 BRAF CCND1 CDKN2A EPCAM ERBB2 KDR
5 embryo MP:0005380 10.48 ERBB2 KDR KIT KRAS PTGS2 SMAD4
6 endocrine/exocrine gland MP:0005379 10.47 CCND1 CDH1 CDKN2A EGFR EPCAM ERBB2
7 homeostasis/metabolism MP:0005376 10.47 CDH1 CDKN2A EGFR EPCAM ERBB2 KDR
8 digestive/alimentary MP:0005381 10.46 BRAF CCND1 CDH1 CDKN2A EGFR EPCAM
9 mortality/aging MP:0010768 10.44 KRAS NTRK3 PTGS2 SMAD4 TGFBR2 TP53
10 immune system MP:0005387 10.43 BIRC5 BRAF CCND1 CDH1 CDKN2A EGFR
11 hematopoietic system MP:0005397 10.42 PTGS2 SMAD4 TGFBR2 TP53 VEGFA BIRC5
12 integument MP:0010771 10.36 CDH1 CDKN2A EGFR ERBB2 KDR KIT
13 nervous system MP:0003631 10.33 BRAF CCND1 CDKN2A EGFR EPCAM ERBB2
14 craniofacial MP:0005382 10.32 TGFBR2 TP53 VEGFA BRAF CCND1 EGFR
15 neoplasm MP:0002006 10.29 BRAF CCND1 CDH1 CDKN2A EGFR ERBB2
16 normal MP:0002873 10.28 ERBB2 KDR KIT KRAS NTRK3 PTGS2
17 muscle MP:0005369 10.27 BRAF CDKN2A EGFR ERBB2 KDR KIT
18 liver/biliary system MP:0005370 10.26 BRAF CDKN2A EGFR KDR KIT KRAS
19 no phenotypic analysis MP:0003012 10.21 CDH1 CDKN2A EGFR EPCAM KDR KIT
20 limbs/digits/tail MP:0005371 10.08 EGFR ERBB2 KIT KRAS SMAD4 TP53
21 reproductive system MP:0005389 10.07 TP53 VEGFA BRAF CCND1 CDH1 CDKN2A
22 hearing/vestibular/ear MP:0005377 10.06 BRAF EGFR KIT KRAS NTRK3 TP53
23 respiratory system MP:0005388 9.97 BRAF CCND1 CDKN2A EGFR ERBB2 KDR
24 renal/urinary system MP:0005367 9.92 KRAS PTGS2 SMAD4 TP53 VEGFA BRAF
25 pigmentation MP:0001186 9.85 BRAF CDKN2A EGFR KIT KRAS TP53
26 skeleton MP:0005390 9.77 TP53 VEGFA BRAF CCND1 CDKN2A EGFR
27 vision/eye MP:0005391 9.4 KRAS NTRK3 PTGS2 TGFBR2 TP53 VEGFA

Drugs & Therapeutics for Adenocarcinoma

FDA approved drugs:

(show all 11)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene Approved October 2012
2
Cervarix 17 46 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline Approved October 2009
3
Cyramza 17 46 RAMUCIRUMAB Eli Lilly Approved April 2014
4
Eloxatin 17 46 OXALIPLATIN Sanofi-aventis Approved August 2002
5
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006
6
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
7
Gilotrif 17 46 AFATINIB DIMALEATE Boehringer Ingelheim Approved July 2013
8
Herceptin 17 46 TRASTUZUMAB Genentech Approved October 1998
9
Iressa 17 46 GEFITINIB AstraZeneca Approved May 2003
10
Sutent 17 46 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
11
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer Approved May 1996

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 908)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
2
Clarithromycin Approved Phase 4 81103-11-9 84029
3
Metronidazole Approved Phase 4,Phase 2,Phase 1 443-48-1 4173
4
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
5
Menthol Approved Phase 4,Phase 3,Phase 2,Early Phase 1 2216-51-5 16666
6
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
7
Propranolol Approved, Investigational Phase 4,Phase 2 525-66-6 4946
8
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 142217-69-4 153941
9
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
10
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
11
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
12
Ethiodized oil Approved Phase 4,Phase 2,Phase 3,Phase 1 8008-53-5
13
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 284461-73-0 216239 406563
14
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
15
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
16
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
17
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
18
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
19
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
20
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
21
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
22
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
23
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
24
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
25
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
26
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
27
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
28
Levoleucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68538-85-2
29
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
30
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
31
Zinc Approved Phase 4,Phase 1 7440-66-6 32051 23994
32
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
33
Axitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 319460-85-0 6450551
34
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
35
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
36
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
37
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
38
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
39
Iron Approved Phase 4,Phase 3,Phase 1 7439-89-6 23925
40
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
41
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
42
Prilocaine Approved Phase 4 721-50-6 4906
43
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
44
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
45
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
46
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
47
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
48
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
49
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
50
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4
2 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
3 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
4 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
5 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
6 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
7 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
8 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4
9 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4
10 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4
11 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4
12 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
13 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
14 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
15 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4
16 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
17 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
18 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
19 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
20 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4
21 A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma Completed NCT00097578 Phase 4
22 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4
23 Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion Completed NCT01451034 Phase 4
24 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4
25 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
26 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4
27 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4
28 Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection Completed NCT00844675 Phase 4
29 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4
30 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
31 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Completed NCT01661166 Phase 4
32 Prospective Randomized Study of SILS Versus CLS for Rectal Cancer Completed NCT01579721 Phase 4
33 Reduction in Symptomatic Esophageal Stricture Formation Completed NCT02039115 Phase 4
34 Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET Completed NCT00904410 Phase 4
35 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4
36 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4
37 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Completed NCT00721175 Phase 4
38 Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients Completed NCT03007225 Phase 4
39 Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail Completed NCT02961998 Phase 4
40 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4
41 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4
42 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
43 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4
44 Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion Completed NCT01952353 Phase 4
45 Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC). Completed NCT01798160 Phase 4
46 Sorafenib in Elderly mRCC Completed NCT01728948 Phase 4
47 Hepatic Xenetix-CT Perfusion Completed NCT01639703 Phase 4
48 Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus Completed NCT01600196 Phase 4
49 Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis Completed NCT01575574 Phase 4
50 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: adenocarcinoma

Genetic Tests for Adenocarcinoma

Genetic tests related to Adenocarcinoma:

id Genetic test Affiliating Genes
1 Adenocarcinoma 29

Anatomical Context for Adenocarcinoma

MalaCards organs/tissues related to Adenocarcinoma:

39
Lung, Prostate, Colon, Breast, Cervix, Pancreas, Lymph Node

Publications for Adenocarcinoma

Articles related to Adenocarcinoma:

(show top 50) (show all 14478)
id Title Authors Year
1
Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma. ( 28139510 )
2017
2
Identification of aberrantly expressed long non-coding RNAs in stomach adenocarcinoma. ( 28484081 )
2017
3
Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. ( 27863258 )
2017
4
Prognostic implications of RASAL1 expression in oesophagogastric adenocarcinoma. ( 28011578 )
2017
5
Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma. ( 28179319 )
2017
6
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma. ( 28168205 )
2017
7
miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma. ( 28012229 )
2017
8
Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. ( 28044374 )
2017
9
A microRNA expression signature as a predictor of survival for colon adenocarcinoma. ( 27881005 )
2017
10
High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases. ( 27976463 )
2017
11
Prognostic significance of autophagy-related proteins expression in resected human gastric adenocarcinoma. ( 28224423 )
2017
12
Lung adenocarcinoma and adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1. ( 28070481 )
2017
13
The role of extent of surgical resection and lymph node assessment for clinical stage I pulmonary lepidic adenocarcinoma: An analysis of 1,991 patients. ( 28082103 )
2017
14
Whole genome sequencing analysis of lung adenocarcinoma in Xuanwei, China. ( 28083984 )
2017
15
Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression. ( 27887846 )
2017
16
Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. ( 27814273 )
2017
17
Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues. ( 28088229 )
2017
18
Impact of Radiofrequency Ablation Treatment of Barrett's Esophagus on Esophageal Adenocarcinoma: A Comparative Modeling Analysis. ( 28089850 )
2017
19
Overexpression of miR-519d in lung adenocarcinoma inhibits cell proliferation and invasion via the association of eIF4H. ( 28351305 )
2017
20
ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features. ( 28364271 )
2017
21
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. ( 28062705 )
2017
22
Knockdown of PARP6 or survivin promotes cell apoptosis and inhibits cell invasion of colorectal adenocarcinoma cells. ( 28260087 )
2017
23
Expressions of insulin-like growth factor receptor-1 and cezanne-1 in lung adenocarcinoma. ( 28365890 )
2017
24
Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. ( 28088657 )
2017
25
Lung adenocarcinoma expressing receptor for advanced glycation end-products with primary systemic AL amyloidosis: a case report and literature review. ( 28056871 )
2017
26
Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. ( 28422979 )
2017
27
Ovol2 gene inhibits the Epithelial-to-Mesenchymal Transition in lung adenocarcinoma by transcriptionally repressing Twist1. ( 27884772 )
2017
28
18F-FDG PET/CT of Seminal Vesicle Metastasis From Ascending Colon Adenocarcinoma. ( 28005644 )
2017
29
Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. ( 28315433 )
2017
30
BAG3 Protein Is Over-Expressed in Endometrioid Endometrial Adenocarcinomas. ( 27414463 )
2017
31
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas. ( 26567008 )
2017
32
Novel quantitative analysis of the S100P protein combined with endoscopic ultrasound-guided fine needle aspiration cytology in the diagnosis of pancreatic adenocarcinoma. ( 28260012 )
2017
33
DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. ( 28339284 )
2017
34
Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. ( 28092365 )
2017
35
Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. ( 28229621 )
2017
36
Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma. ( 27026568 )
2017
37
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )
2017
38
Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. ( 28091594 )
2017
39
Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence. ( 28216140 )
2017
40
Re-evaluation of Phenotypic Expression in Differentiated-type Early Adenocarcinoma of the Stomach. ( 28088838 )
2017
41
The pseudogene-derived long noncoding RNA SFTA1P is down-regulated and suppresses cell migration and invasion in lung adenocarcinoma. ( 28231733 )
2017
42
Expression of ribophorine II is a promising prognostic factor in human gastric adenocarcinoma. ( 28035352 )
2017
43
Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome. ( 28501935 )
2017
44
Metastatic Mucinous Adenocarcinoma and Carcinoid Tumor Arising From a Mature Cystic Teratoma of a Horseshoe Kidney. ( 28083486 )
2017
45
miRa89181ba895p mediates TGFa89I^1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells. ( 28534939 )
2017
46
Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases. ( 28196904 )
2017
47
Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. ( 28526810 )
2017
48
Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma. ( 28220683 )
2017
49
Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China. ( 27888377 )
2017
50
Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. ( 28060763 )
2017